lecanemab-irmb
Biogen announces phase 2 data for cutaneous lupus erythematosus
The results for litifilimab support the potential to achieve rapid and durable improvements in skin disease activity
Galimedix establishes Alzheimer’s Disease Scientific Advisory Board
The Board will advise Galimedix on scientific and clinical strategy
Biogen and Eisai’s Leqembi study shows nearly 83% of early Alzheimer’s patients remained stable or improved
The real-world findings support the long-term benefits of continuous treatment
Alzheimer’s groups call for urgent global focus on women’s brain health
New op-ed published by leaders from the Women’s Alzheimer’s Movement at Cleveland Clinic, Alzheimer’s Research UK and the Alzheimer’s Association
Biogen to acquire RayThera in $1bn deal
The acquisition will expand the company’s immunology pipeline
Biogen’s salanersen gets FDA Breakthrough Therapy Designation for SMA
In the study, there were improvements in motor function as well as a slowing of neurodegeneration
Biogen agrees $850m felzartamab rights deal with TJ Biopharma
The agreement gives Biogen full global rights to the investigational antibody across immune-mediated diseases
MHRA authorises Biogen’s higher-dose Spinraza for SMA treatment
SMA is a rare genetic neuromuscular condition affecting around 1,600 people in the UK
AC Immune amends agreement with Lilly to develop potential Alzheimer’s treatment
The agreement covers the development of new lead tau morphomer candidates
Biogen to acquire Apellis in $5.6bn deal
The deal will enhance Biogen’s growth portfolio in immunology and rare disease
Eisai and Biogen’s new data shows Alzheimer’s patients choose to stay on Leqembi long-term
The findings were presented at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases in Denmark
Biogen’s litifilimab receives FDA Breakthrough Therapy Designation for lupus
Therapies like topical steroids manage symptoms but there is currently no cure